Allogeneic bone marrow transplantation (BMT) currently constitutes the major therapeutic treatment option for a number of hematological malignancies, inherited disorders of hematopoiesis and certain in-born errors of metabolism. For leukemias and other neoplastic diseases, it is now appreciated that an important benefit of allogeneic BMT is a graft-vs-leukemia (GVL) effect. Unfortunately, the more widespread application of allogeneic BMT remains severely limited by the complications of graft-versus-host disease (GVHD), the associated morbid effects of long-term immunosuppression and problems of failure of engraftment. The experiments described in this proposal are aimed at overcoming these obstacles by the transplantation of purified hematopoietic stem cells (HSCs). The rationale for this approach is that purified HSCs lack the mature elements which allow the graft to mount a response against the host, thus engraftment of such cells will not cause GVHD, and in the absence of GVHD the need for long-term immunosuppression will be eliminated. An important adjunctive benefit derived from the successful transplantation of allogeneic HSCs, is that the resultant chimeric individuals are immunologically tolerant to subsequent donor-matched cell infusions. Thus, in the context of HSC engraftment it will be possible to infuse populations of donor derived cells that have been selected to confer GVL effects (but not GVHD) without the problems of host resistance to these tumor suppressing cells. In previous studies from our laboratory we isolated and characterized a purified hematopoietic stem cell population from mice. These cells are capable of self-renewal, give rise to all blood lineages, and are approximately 2000-fold enriched for their ability to radioprotect lethally irradiated mice. We have recently successfully achieved engraftment of these cells across major immune barriers and have begun to define some of the requirements to achieve durable engraftment. The major goals of the experiments outlined in this proposal are as follows: (1) To understand the cellular and molecular basis of resistance to allogeneic HSC and bone marrow transplants; (2) to develop rationale based therapies that allow stable allogeneic HSC engraftment with limited host morbidity; (3) to characterize and clone the cell populations, as well as the receptors from cells that confer GVL, so that it may become possible to produce """"""""customized"""""""" transplants for neoplastic diseases in the future. Research in Project V is related to experiments performed in other subprojects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA049605-12
Application #
6395681
Study Section
Project Start
2000-03-13
Project End
2001-01-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
12
Fiscal Year
2000
Total Cost
$221,448
Indirect Cost
Name
Stanford University
Department
Type
DUNS #
800771545
City
Stanford
State
CA
Country
United States
Zip Code
94305
Zerboni, Leigh; Sung, Phillip; Sommer, Marvin et al. (2018) The C-terminus of varicella-zoster virus glycoprotein M contains trafficking motifs that mediate skin virulence in the SCID-human model of VZV pathogenesis. Virology 523:110-120
Muffly, Lori; Sheehan, Kevin; Armstrong, Randall et al. (2018) Infusion of donor-derived CD8+ memory T cells for relapse following allogeneic hematopoietic cell transplantation. Blood Adv 2:681-690
Tavallaee, Mahkam; Steiner, David F; Zehnder, James L et al. (2018) Coexistence of BRAF V600E and TERT Promoter Mutations in Low-grade Serous Carcinoma of Ovary Recurring as Carcinosarcoma in a Lymph Node: Report of a Case. Int J Gynecol Pathol :
Du, Jing; Paz, Katelyn; Thangavelu, Govindarajan et al. (2017) Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells. Blood 129:3121-3125
Spinner, Michael A; Fernández-Viña, Marcelo; Creary, Lisa E et al. (2017) HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity. Blood Adv 1:1347-1357
Costa, Helio A; Neal, Joel W; Bustamante, Carlos D et al. (2017) Identification of a Novel Somatic Mutation Leading to Allele Dropout for EGFR L858R Genotyping in Non-Small Cell Lung Cancer. Mol Diagn Ther 21:431-436
Chen, Yi-Bin; Efebera, Yvonne A; Johnston, Laura et al. (2017) Increased Foxp3+Helios+Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells. Biol Blood Marrow Transplant 23:625-634
Xu, Liwen; You, Xiaoqing; Zheng, PingPing et al. (2017) Methodologic Considerations in the Application of Next-Generation Sequencing of Human TRB Repertoires for Clinical Use. J Mol Diagn 19:72-83
Khodadoust, M S; Luo, B; Medeiros, B C et al. (2016) Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia. Leukemia 30:947-50
Pierini, Antonio; Alvarez, Maite; Negrin, Robert S (2016) NK Cell and CD4+FoxP3+ Regulatory T Cell Based Therapies for Hematopoietic Stem Cell Engraftment. Stem Cells Int 2016:9025835

Showing the most recent 10 out of 307 publications